Grizzly Bulls
Financial research concept

Life Sciences Tools Analytical Instruments Organic Revenue Growth

measures acquisition- and currency-adjusted revenue growth in a life-sciences tools company's analytical instruments segment.

By Lee BaileyPublished Oct 1, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Oct 1, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
10 connected conceptsPart of the reviewed Life Sciences Tools & Biopharma Services Economics; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. Instrument demand drove broad-based organic growth
  2. Organic growth should stay separate from margin conversion
  3. Part of the Life Sciences Tools & Biopharma Services Economics
  4. See It in Company Research
  5. Continue Research

Life sciences tools Analytical Instruments organic revenue growth measures segment revenue growth after removing the effects of acquisitions, divestitures, and currency translation under the issuer's non-GAAP methodology.

Thermo Fisher Scientific reported 7% organic revenue growth in Analytical Instruments for the second quarter of 2026. Segment revenue was $1.847B, up from $1.728B a year earlier.

Instrument demand drove broad-based organic growth

Thermo Fisher said organic growth occurred across all three businesses in the segment and was led by electron microscopy.

Because acquisition and currency effects were both reported at 0% for the quarter, the 7% reported segment growth also matched the organic rate.

Organic growth should stay separate from margin conversion

Strong instrument demand can lift revenue without revealing how much incremental profit the segment converts.

Pair the growth rate with Analytical Instruments segment income margin and Life Sciences Solutions organic revenue growth.

Primary source: Thermo Fisher Scientific Q2 2026 Form 10-Q.

Part of the Life Sciences Tools & Biopharma Services Economics

Connects Thermo Fisher's four operating segments through issuer-defined organic revenue growth, segment-income conversion, and disclosed business-level contributions to reported growth.

Browse the full operating model in Company Analysis →
Where this concept fits

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare analytical instrument organic growth

Compare acquisition- and currency-adjusted analytical instrument growth while keeping instrument demand and portfolio effects separate.

Continue research

Explore more topics in the Financial Research Encyclopedia.